Form 4: Avidity Biosciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Teresa McCarthy, Chief Human Resources Officer at Avidity Biosciences, exercised stock options to acquire 25,000 shares of common stock at a price of $14.22 per share.
• Concurrently, Ms. McCarthy sold 25,000 shares of common stock at a weighted-average price of $33.2642 per share.
• The transactions were executed on December 16, 2024, under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2024.
• Following these transactions, Ms. McCarthy beneficially owns 94,018 shares of Avidity Biosciences common stock directly and 57,500 stock options.

Sentiment

Score: 6

Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, which is neither particularly positive nor negative. The sentiment is neutral to slightly positive due to the profit made by the executive.

Positives

• The execution of the 10b5-1 plan indicates a pre-planned and transparent approach to stock transactions by the executive.
• The exercise of options at $14.22 and sale at a higher price of $33.2642 demonstrates a potential profit for the executive.

Negatives

• The sale of 25,000 shares by a company executive could be perceived negatively by some investors, although it is part of a pre-arranged plan.

Risks

• Executive stock sales, even under a 10b5-1 plan, can sometimes be interpreted as a lack of confidence in the company's future performance by some investors.
• The market may react to the sale of shares by an executive, potentially causing short-term price fluctuations.

Industry Context

This is a routine filing related to executive stock transactions and is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
• The vesting schedule of the stock options, with monthly vesting over four years, is also a typical arrangement for executive compensation in the industry.
• The price range of the share sales, from $32.33 to $33.85, is within the expected range for market transactions of this type.

Stakeholder Impact

• Shareholders may view the executive's stock sale as a neutral event, given it was part of a pre-arranged plan.
• Employees may see the executive's stock transactions as part of standard compensation practices.

Key Dates

Keywords

Avidity Biosciences, stock options, insider trading, Rule 10b5-1, executive compensation, share sale, Teresa McCarthy